STAB2 and atherosclerosis: Stab1 and Stab2 single inhibition mediates beneficial effects in atherosclerosis development (Manta et al., 2022), anti‐Stab1 inhibition is in clinical trials in immune‐oncology (Virtakoivu et al., 2021).